Quantcast
Home > Quotes > CTMX

CytomX Therapeutics, Inc. Common Stock (CTMX) Quote & Summary Data

CTMX 
$14.42
*  
0.33
2.34%
Get CTMX Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading CTMX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CTMX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
36
Today's High / Low
$ 14.46 / $ 13.83
Share Volume
243,440
50 Day Avg. Daily Volume
390,273
Previous Close
$ 14.09
52 Week High / Low
$ 35 / $ 12.51
Market Cap
649,002,440
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.26
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.78

Intraday Chart

Shares Traded

Share Volume:
243,440
50 Day Avg. Daily Volume:
390,273

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.26

Trading Range

The current last sale of $14.42 is 15.27% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.46 $ 35
 Low: $ 13.83 $ 12.51

Company Description (as filed with the SEC)

We are a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapeutics. We are pioneering a novel class of investigational antibody therapeutics, based on our Probody(TM) technology platform, for the treatment of cancer. The Probody therapeutic approach is designed to more specifically target antibody therapeutics to the tumor microenvironment and reduce drug activity in healthy tissue and in circulation. We believe this approach has the potential to make meaningful enhancements to the combined efficacy and safety profile of antibody therapeutics known as the therapeutic window. We believe that Probody therapeutics have the potential to create or widen the therapeutic window for certain antibody therapeutics, allowing for the development of new approaches to the treatment of cancer.  ... More ...  


Risk Grade

Where does CTMX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.05
Open Date:
Dec. 10, 2018
Close Price:
$ 14.42
Close Date:
Dec. 10, 2018

Consensus Recommendation

Analyst Info